Methotrexate

Generic Name
Methotrexate
Brand Names
Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
Drug Type
Small Molecule
Chemical Formula
C20H22N8O5
CAS Number
59-05-2
Unique Ingredient Identifier
YL5FZ2Y5U1
Background

Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.

Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.

Methotrexate was granted FDA approval on 7 December 1953.

Indication

Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.

Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
Associated Therapies
Medically induced abortion
Clinical Trials
Related News

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

First Posted Date
2004-11-09
Last Posted Date
2017-03-21
Lead Sponsor
Children's Oncology Group
Target Recruit Count
168
Registration Number
NCT00096135
Locations
🇺🇸

CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States

🇺🇸

Childrens Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

and more 150 locations

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

First Posted Date
2004-10-05
Last Posted Date
2012-07-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
46
Registration Number
NCT00002524
Locations
🇺🇸

MD Anderson Cancer Center Orlando, Orlando, Florida, United States

🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia

First Posted Date
2004-09-13
Last Posted Date
2014-07-25
Lead Sponsor
Children's Oncology Group
Target Recruit Count
59
Registration Number
NCT00003671
Locations
🇺🇸

Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States

🇺🇸

West Virginia University Hospitals, Morgantown, West Virginia, United States

🇺🇸

Madigan Army Medical Center, Tacoma, Washington, United States

and more 54 locations

Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

First Posted Date
2004-09-06
Last Posted Date
2014-07-25
Lead Sponsor
Children's Oncology Group
Target Recruit Count
20
Registration Number
NCT00003217
Locations
🇺🇸

Children's Memorial Hospital, Chicago, Chicago, Illinois, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

State University of New York - Upstate Medical University, Syracuse, New York, United States

and more 11 locations

Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

First Posted Date
2004-09-02
Last Posted Date
2015-03-06
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00002790

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

First Posted Date
2004-09-02
Last Posted Date
2014-07-24
Lead Sponsor
Children's Oncology Group
Target Recruit Count
115
Registration Number
NCT00002805
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 35 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date
2004-09-01
Last Posted Date
2017-02-09
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1970
Registration Number
NCT00002744
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Children's Hospital of Columbus, Columbus, Ohio, United States

🇺🇸

Children's Hospital and Medical Center - Seattle, Seattle, Washington, United States

and more 31 locations

Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-08-31
Last Posted Date
2010-03-30
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
30
Registration Number
NCT00002554

Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

First Posted Date
2004-08-30
Last Posted Date
2013-06-26
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00002489
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Leukemia
Lymphoma
First Posted Date
2004-08-30
Last Posted Date
2013-06-20
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00002471
Locations
🇺🇸

Kaplan Cancer Center, New York, New York, United States

🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy